Patents by Inventor Darren Paul Wallace

Darren Paul Wallace has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LKB1-AMPK activators for therapeutic use in polycystic kidney disease
    Patent number: 10450305
    Abstract: Compounds can be used for treating polycystic kidney disease (PKD). As such, these compounds can be used in associated methods. The methods can include: method of modulating (e.g., activating) Liver kinase B1 (LKB1); method of modulating (e.g., decreasing activity) mammalian target of rapamycin (mTOR). The methods may include introducing the compound in a therapeutically effective amount to a subject having PKD. The methods may include introducing the compound in a therapeutically effective amount to a subject having Autosomal Dominant PKD. The compounds can be used in methods of treating a disease modulated by a mTOR pathway, which can include introducing the compound in a therapeutically effective amount to a subject having the disease modulated by the mTOR pathway.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: October 22, 2019
    Assignee: The University of Kansas
    Inventors: Darren Paul Wallace, Bhaskar Chandra Das
  • LKB1-AMPK ACTIVATORS FOR THERAPEUTIC USE IN POLYCYSTIC KIDNEY DISEASE
    Publication number: 20190106415
    Abstract: Compounds can be used for treating polycystic kidney disease (PKD). As such, these compounds can be used in associated methods. The methods can include: method of modulating (e.g., activating) Liver kinase B1 (LKB1); method of modulating (e.g., decreasing activity) mammalian target of rapamycin (mTOR). The methods may include introducing the compound in a therapeutically effective amount to a subject having PKD. The methods may include introducing the compound in a therapeutically effective amount to a subject having Autosomal Dominant PKD. The compounds can be used in methods of treating a disease modulated by a mTOR pathway, which can include introducing the compound in a therapeutically effective amount to a subject having the disease modulated by the mTOR pathway.
    Type: Application
    Filed: December 7, 2018
    Publication date: April 11, 2019
    Inventors: Darren Paul Wallace, Bhaskar Chandra Das
  • LKB1-AMPK activators for therapeutic use in polycystic kidney disease
    Patent number: 10174012
    Abstract: Compounds are provided for use in treating polycystic kidney disease (PKD) and in associated methods that include a method of modulating (e.g., activating) Liver kinase B1 (LKBI); and a method of modulating (e.g., decreasing activity) mammalian target of rapamycin (mTOR). The methods may include introducing the compound in a therapeutically effective amount to a subject having PKD. The methods may include introducing the compound in a therapeutically effective amount to a subject having Autosomal Dominant PKD. The compounds can be used in methods of treating a disease modulated by a mTOR pathway, which can include introducing the compound in a therapeutically effective amount to a subject having the disease modulated by the mTOR pathway. The disease modulated by mTOR is selected from the group consisting of multiple types of cancer, leukemia, kidney disease, obesity, neuro disorders and alcohol-related chronic diseases.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: January 8, 2019
    Assignee: The University of Kansas
    Inventors: Darren Paul Wallace, Bhaskar Chandra Das
  • LKB1-AMPK ACTIVATORS FOR THERAPEUTIC USE IN POLYCYSTIC KIDNEY DISEASE
    Publication number: 20170334892
    Abstract: Compounds are provided for use in treating polycystic kidney disease (PKD) and in associated methods that include a method of modulating (e.g., activating) Liver kinase B1 (LKBI); and a method of modulating (e.g., decreasing activity) mammalian target of rapamycin (mTOR). The methods may include introducing the compound in a therapeutically effective amount to a subject having PKD. The methods may include introducing the compound in a therapeutically effective amount to a subject having Autosomal Dominant PKD. The compounds can be used in methods of treating a disease modulated by a mTOR pathway, which can include introducing the compound in a therapeutically effective amount to a subject having the disease modulated by the mTOR pathway. The disease modulated by mTOR is selected from the group consisting of multiple types of cancer, leukemia, kidney disease, obesity, neuro disorders and alcohol-related chronic diseases.
    Type: Application
    Filed: November 3, 2015
    Publication date: November 23, 2017
    Inventors: Darren Paul Wallace, Bhaskar Chandra Das